Mussini C, Cossarizza A, Sabin C, Babiker A, de Luca A, Bucher HC, Fisher M, Rezza G, Porter K, Dorrucci M, et al. Decline of CD4+ T-cell count before start of therapy and immunological response to treatment in antiretroviral-naive individuals. Aids. 2011;25:1041–1049.
Jarrin I, Pantazis N, Gill JM, Geskus R, Perez-Hoyos S, Meyer L, Prins M, Touloumi G, Johnson A, Hamouda O, et al. Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia. Clinical infectious diseases. 2011;54:111–118.
Jaffe HW, De Stavola BL, Carpenter LM, Porter K, Cox DR, Collaboration C, others.
Immune reconstitution and risk of Kaposi sarcoma and non-Hodgkin lymphoma in HIV-infected adults. Aids. 2011;25:1395–1403.
van der Helm JJ, Prins M, Del Amo J, Bucher HC, Chene G, Dorrucci M, Gill J, Hamouda O, Sannes M, Porter K, et al. The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. Aids. 2011;25:1083–1091.
Funk MJ, Fusco JS, Cole SR, Thomas JC, Porter K, Kaufman JS, Davidian M, White AD, Hartmann KE, Eron Jr JJ, et al. Timing of HAART initiation and clinical outcomes among HIV-1 seroconverters. Archives of internal medicine. 2011;171:1560.
Lodi S, Phillips A, Touloumi G, Geskus R, Meyer L, Thiebaut R, Pantazis N, Del Amo J, Johnson AM, Babiker A, et al. Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds< 200,< 350, and< 500 cells/mm3: assessment of need following changes in treatment guidelines. Clinical infectious diseases. 2011;53:817–825.
